rs501120 — CXCL12

CXCL12 at 10q11 — A Chemokine Amplifier That Raises Cardiovascular Risk

A region of chromosome 10 sitting roughly 80 kilobases downstream of the CXCL12 gene¹¹ CXCL12 gene
C-X-C motif chemokine ligand 12, also known as SDF-1 (stromal cell-derived factor 1) harbors one of the most consistently replicated non-obvious GWAS signals for coronary artery disease. rs501120 does not change any protein. What it appears to do is turn up the volume on CXCL12 production — and chronically elevated CXCL12 promotes the vascular inflammation and plaque progression that underlie most heart attacks.

The Mechanism

CXCL12 signals through two receptors, CXCR4 and ACKR3 (CXCR7), orchestrating the recruitment of bone-marrow progenitor cells to sites of vascular injury and regulating inflammatory cell trafficking in arterial walls. At physiological levels it supports vascular repair. When chronically elevated, however, it drives endothelial dysfunction, promotes neointimal hyperplasia, and accelerates atherosclerotic plaque formation²² atherosclerotic plaque formation
CXCL12 derived from endothelial cells promotes atherosclerosis in animal models and human data.

rs501120 sits in a non-coding regulatory region. The T (risk) allele is associated with measurably higher circulating CXCL12 protein — suggesting the locus influences gene expression or mRNA stability, though the precise regulatory element has not been pinpointed. In strong linkage disequilibrium³³ linkage disequilibrium
LD, correlated inheritance, with the nearby rs1746048 (r² ≈ 1.0), both variants tag the same underlying haplotype.

The Evidence

The original signal emerged in the Wellcome Trust Case Control Consortium (WTCCC) and German MI Family Study⁴⁴ Wellcome Trust Case Control Consortium (WTCCC) and German MI Family Study
Samani et al. 2007 NEJM, 1,926 CAD cases, 2,938 controls, where combined analysis reached OR 1.33 (p = 9.46 × 10⁻⁸) — genome-wide significance. This placed the 10q11 locus among the earliest replicated novel GWAS hits for coronary artery disease.

The association held up in a large European replication: Coronary Artery Disease Consortium, 2009⁵⁵ Coronary Artery Disease Consortium, 2009
11,550 cases, 11,205 controls across 9 European studies confirmed OR 1.11 (95% CI 1.05–1.18, p = 4.34 × 10⁻⁴). A notable finding was a sex-specific effect: the risk was significant in women (OR 1.29) but not in men (OR 1.03, p = 0.39), suggesting the variant's cardiovascular impact may be modulated by sex hormones or other sex-linked biology.

Functional support came from Mehta et al. 2011 Eur Heart J⁶⁶ Mehta et al. 2011 Eur Heart J
2,939 participants, two independent cohorts: T allele carriers had higher plasma CXCL12 concentrations (TT 2.34 ± 0.49 vs CC 2.23 ± 0.53 ng/mL, replication p = 0.007, meta-analysis p = 6 × 10⁻⁴), connecting the genetic signal directly to a measurable biochemical intermediate.

Elevated plasma CXCL12 independently predicts adverse outcomes in people already diagnosed with CAD: Ghasemzadeh et al. 2015 Atherosclerosis⁷⁷ Ghasemzadeh et al. 2015 Atherosclerosis
785 CAD patients, 2.6-year follow-up found a 4.8-fold increased risk of cardiovascular death or MI in those with high CXCL12 levels (HR 4.81, p = 1 × 10⁻⁶), improving risk reclassification by 40% beyond traditional risk factors.

Replication in non-European populations adds breadth: a Chinese Han study⁸⁸ Chinese Han study
368 ischemic stroke cases, 381 controls found the C (protective) allele and CT/CC genotypes associated with lower ischemic stroke risk, particularly in men, consistent with the 10q11 locus influencing cerebrovascular as well as coronary endpoints.

Practical Actions

For TT homozygotes (~74% of Europeans), the signal justifies earlier and more intensive cardiovascular monitoring — specifically requesting a high-sensitivity CRP and lipoprotein(a) panel to contextualize the genotype-based risk. Statin therapy has been shown to reduce circulating CXCL12 levels⁹⁹ reduce circulating CXCL12 levels
Dose-dependent statin effect on CXCL12, PMC3560987, providing a mechanistic rationale, in addition to their established LDL-lowering benefit, for prioritizing statin therapy discussions in TT individuals at intermediate cardiovascular risk who might otherwise be in a "watchful waiting" category.

Nitrate-rich vegetables (beetroot, leafy greens) support endothelial nitric oxide production via a CXCL12-independent pathway, providing a dietary complement to pharmacological approaches for people with the TT genotype. Avoid high-dose supplement regimens marketed as "boosting stem cell mobilization" — several promote CXCL12/CXCR4 activation, which would be counterproductive in the context of this variant.

Interactions

rs501120 is in near-perfect LD (r² ≈ 1.0) with rs1746048, another CXCL12 downstream variant with an independent GWAS signal, meaning the two variants effectively tag the same haplotype and compound actions between them are not meaningful — they will nearly always be inherited together.

rs1801157 in the 3′UTR of CXCL12 has been investigated separately; a meta-analysis found it is not independently associated with CAD risk, though it may influence CXCL12 mRNA stability by a different mechanism.